Skip to main content
. 2021 Jul 12;4:859. doi: 10.1038/s42003-021-02375-9

Fig. 9. FEC + oHSV-1 induces dichotomous response, with responders having upregulation of B-cell receptor signaling pathways and downregulation of genes associated with immunosuppressive phenotypes.

Fig. 9

a 3-D cluster plot showing the RNA expression correlations between mice treated with FEC + oHSV-1 (non-responders = pink; responders = purple). b Heat map showing the normalized expression values of genes associated with B-cell receptor signaling pathways, across all FEC + oHSV-1 samples. c CD19 mRNA expression was compared between responders (n = 23) versus non-responders (n = 30) to FEC treatment in a cohort of HER2(-) ER(-) breast cancer patients [AUC = 0.657 Mann–Whitney p value = 0.054]. d CD19 mRNA expression was compared between responders (n = 84) versus non-responders (n = 219) to FEC treatment in a cohort of all breast cancer patients [AUC = 0.729, Mann–Whitney p value < 0.001]. Response defined as complete pathological response versus residual disease after completing therapy. *BCR B Cell Receptor.